Bristol-Myers Squibb (BMY)

AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.

Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.

Consider this pharma company's turnaround, not its dividend, its main appeal.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Bristol Myers Squibb (NYSE: BMY) today announced it will present new data from its oncology portfolio and pipeline across a broad range of solid tumors at the European Society for Medical Oncology (ESMO) 2026 Congress to be held October 23-27 in Madrid, Spain. Across 12 oral presentations and nearly 60 disclosures, the company will highlight progress across differentiated therapeutic approaches, including:

It has been a volatile year for the biotech.

Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate.

Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review, and safety results consistent with the known RYZ101 safety profile. ACTION-1 is a randomized Phase 3 clinical trial evaluating RYZ101 (225Ac-DOTATATE) versus investigator's choice of standard of care (high-dose or high-frequency long-acting somatostatin analogues, everolimus, or sunitinib) in patients with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have progressed following Lutetium-177 (Lu177)-based therapy.

Bristol Myers Squibb (NYSE: BMY) today announced topline results from the pivotal Phase 3 ALOFT-IPF trial evaluating the efficacy, safety and tolerability of admilparant, a potential first-in-class, orally administered, potent and selective lysophosphatidic acid receptor 1 (LPA1) antagonist, in adults with idiopathic pulmonary fibrosis (IPF). The trial evaluated two dose levels of admilparant, 60 mg and 120 mg, twice daily for ≥52 weeks against placebo (1:1:1).

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.

 

If you are looking for yield and can think long-term, you'll want to consider Bristol Myers Squibb and Realty Income today.